NVS vs. TECH: Novartis vs. Bio-Techne Stock Comparison

Company Profile

Novartis (NVS) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NVS is classified in Pharmaceuticals while TECH is classified in Life Sciences Tools & Services.

Bio-Techne (TECH) trades as ordinary local shares, while Novartis (NVS) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Novartis (NVS) at 24.33% and Bio-Techne (TECH) at 8.33% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both Novartis (NVS) at 17.49% and Bio-Techne (TECH) at 14.00% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Novartis (NVS) at 34.27% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Novartis (NVS) at 9.57% and Bio-Techne (TECH) at -0.38% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Bio-Techne (TECH) at 152.17% sits in the top EPS growth quartile, while Novartis (NVS) at 21.81% is closer to the peer norm — faster per-share earnings growth for TECH.

Growth Metrics

Financial Strength

Both Novartis (NVS) at 0.88 and Bio-Techne (TECH) at 2.28 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Bio-Techne (TECH) at 0.13 carries an industry-typical debt-to-equity mix, while Novartis (NVS) at 1.29 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Both Novartis (NVS) at 2.88% and Bio-Techne (TECH) at 0.44% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Novartis (NVS) at 90.46% and Bio-Techne (TECH) at 27.59% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Novartis (NVS) at 31.02 is near its industry’s usual P/E ratio, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — TECH needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Novartis (NVS) at 5.35 and Bio-Techne (TECH) at 9.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Bio-Techne (TECH) at 5.28 is valued about in line with its industry on P/B ratio, while Novartis (NVS) at 8.25 carries an above-peer premium to book — NVS is pricier on assets.

Valuation Metrics